Arcus Biosciences Inc. Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy P

The "Metastatic Colorectal cancer - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com''s offering. The publisher''s, "Metastatic Colorectal cancer - Pipeline Insight, 2022," report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in Metastatic Colorectal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. A detailed picture of the Metastatic Colorectal cancer pipeline landscape is provided which includes the disease overview and Metastatic Colorectal cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Colorectal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 428.32% and 3,898.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th

Arcus Biosciences press release (RCUS): Q4 GAAP EPS of $3.71 beats by $4.33.Revenue of $354.5M (+3635.5% Y/Y) beats by $305.07M.“Arcus is starting 2022 with a strong cash position…

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update on its six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a and PD-1 across common cancers, including lung

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 428.32% and 3,898.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th

Related Stocks: RCUS , APLS , BBIO , FDMT , IMAB , STOK , ITOS , KROS , KDNY , IMVT , OLMA , CMPX , CRIS , ISEE , NGM , IKNA , PMVP , EWTX ,

Why are investors unenthused with the biotech giant's earnings report?

Both offer yields more than twice what the S&P 500 provides.

Gilead Sciences Inc. beat Wall Street's expectations for revenue in the fourth quarter, but the drugmaker's earnings were hit by $2 billion in unexpected costs, most of it due to a legal settlement.

Arcus Biosciences (RCUS) granted six new employees options to buy a total of 38,850 common shares at $31.75 apiece and restricted stock units to acquire a total of 925 shares.The…

While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious

Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add

Related Stocks: RCUS ,